Tech Company Financing Transactions
Afferent Pharmaceuticals Funding Round
On 7/8/2015, Afferent Pharmaceuticals secured $55 million in Series C investment from Fidelity Management & Research Company, Jennison Associates and New Leaf Venture Partners.
Transaction Overview
Company Name
Announced On
7/8/2015
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds will fund the advancement of the company's first-in-class drug candidate AF-219 for the treatment of pathologic cough, including for cough in IPF patients, as well as advancement of its next candidate compound to the clinic for cardiovascular and other diseases. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2755 Campus Dr. 100
San Mateo, CA 94403
USA
San Mateo, CA 94403
USA
Phone
Website
Email Address
Not Recorded
Overview
A leader in the development of novel, selective small molecules that target the P2X3 purinergic receptor, for the treatment of a range of debilitating symptoms and sensory disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kathleen Glaub
Chief Medical Officer
Michael Kitt
Chief Scientific Officer
Anthony Ford
VP - Operations
Peter Butera
Browse more venture capital transactions:
Prev: 7/8/2015: KnowledgeHound venture capital transaction
Next: 7/8/2015: Babbel venture capital transaction
Share this article
News on VC Transactions
We do our best to document tech company VC transactions. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs